Abstract Number: 3222 • 2015 ACR/ARHP Annual Meeting
Repeated Administration of Dapirolizumab Pegol (DZP) Appears Safe and Well Tolerated in Patients with Systemic Lupus Erythematosus (SLE) and Is Accompanied By an Improvement in Disease Activity: Results from a Phase 1 Study
Background/Purpose: CD40 ligand (CD40L) regulates interactions between T cells, B cells, and antigen presenting cells. Considerable evidence suggests CD40L blockade might provide an effective treatment…